Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Adès, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E Carraway, Naval Daver, Maria Díez-Campelo, Theo de Witte, Amy E DeZern, Fabio Efficace, Guillermo Garcia-Manero, Jacqueline S Garcia, Ulrich Germing, Aristoteles Giagounidis, Elizabeth A Griffiths, Robert P Hasserjian, Eva Hellström-Lindberg, Marcelo Iastrebner, Rami Komrokji, Austin G Kulasekararaj, Luca Malcovati, Yasushi Miyazaki, Olatoyosi Odenike, Valeria Santini, Guillermo Sanz, Phillip Scheinberg, Reinhard Stauder, Arjan A van de Loosdrecht, Andrew H Wei, Mikkael A Sekeres, Pierre Fenaux
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival)...
April 27, 2023: Blood
#22
MULTICENTER STUDY
Miguel D Cantu, Rashmi Kanagal-Shamanna, Sa A Wang, Tapan Kadia, Carlos E Bueso-Ramos, Sanjay S Patel, Julia T Geyer, Wayne Tam, Yazan Madanat, Peng Li, Tracy I George, Meredith M Nichols, Heesun J Rogers, Yen-Chun Liu, Nidhi Aggarwal, Jason H Kurzer, Danielle L V Maracaja, Eric D Hsi, Feras Zaiem, Daniel Babu, Kathryn Foucar, Dorottya Laczko, Adam Bagg, Attilio Orazi, Daniel A Arber, Robert P Hasserjian, Olga K Weinberg
PURPOSE: Therapy-related acute myeloid leukemias (t-AML) are a heterogenous group of aggressive neoplasms that arise following exposure to cytotoxic chemotherapy and/or ionizing radiation. Many therapy-related myeloid neoplasms (t-MN) are associated with distinct chromosomal aberrations and/or TP53 alterations, but little is known about the clinicopathologic and molecular features of normal karyotype t-AML (NK-t-AML) and whether this t-MN subtype is distinctly different from NK de novo AML (NK-dn-AML)...
January 2023: JCO Precision Oncology
#23
JOURNAL ARTICLE
Megan J Fitzpatrick, Vandana Sundaram, Amy Ly, Jeremy S Abramson, Ronald Balassanian, Matthew C Cheung, Stephen L Cook, Lorenzo Falchi, Annabel K Frank, Srishti Gupta, Robert P Hasserjian, Oscar Lin, Steven R Long, Joshua R Menke, Eric Mou, Daniel R Reed, Roberto Ruiz-Cordero, Ashley K Volaric, Linlin Wang, Kwun Wah Wen, Yi Xie, Sara L Zadeh, Dita Gratzinger
BACKGROUND: Few studies have evaluated diagnostic yield of small volume biopsies (SVB) for the diagnosis and management of follicular lymphoma (FL). METHODS: The authors performed a multi-institutional retrospective analysis of SVBs including fine-needle aspiration (FNA) and needle core biopsy (NCB) for initial FL diagnosis and suspected recurrence or transformation of FL. A total of 676 workups beginning with SVB were assessed for the mean number of biopsies per workup, the proportion of workups requiring multiple biopsies, and the proportion with a complete diagnosis including grade, on initial biopsy...
December 27, 2022: Cancer Cytopathology
#24
EDITORIAL
Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia.
Daniel A Arber, Robert P Hasserjian, Attilio Orazi
No abstract text is available yet for this article.
March 2023: American Journal of Hematology
#25
JOURNAL ARTICLE
Ashley K Volaric, Oscar Lin, Ronald Balassanian, Stephen Cook, Lorenzo Falchi, Megan J Fitzpatrick, Annabel K Frank, Srishti Gupta, Robert P Hasserjian, Steven Long, Amy Ly, Joshua R Menke, Eric Mou, Yasodha Natkunam, Daniel R Reed, Roberto Ruiz-Cordero, Linlin Wang, Kwun Wah Wen, Yi Xie, Sara L Zadeh, Dita Gratzinger
Small-volume biopsies (SVBs) including fine-needle aspiration (FNA), cell block, and needle core biopsies (NCB) are increasingly utilized to diagnose and guide the clinical management of lymphoma. We established a multi-institutional interdisciplinary collaboration of cytopathologists, hematopathologists, and oncologists focused on the role of SVB in the management of patients with follicular lymphoma (FL). To assess the performance characteristics of SVB in this setting, we evaluated all consecutive SVBs performed for clinical indications of initial diagnosis, recurrence, or transformation of FL over a 5-year period and focused on the 182 that had at least one subsequent biopsy within 3 months as part of the same clinical work-up...
December 20, 2022: American Journal of Surgical Pathology
#26
REVIEW
Sonam Prakash, Daniel A Arber, Carlos Bueso-Ramos, Robert P Hasserjian, Attilio Orazi
The myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) category includes a heterogeneous group of diseases characterized by the co-occurrence of clinical and pathologic features of both myelodysplastic and myeloproliferative neoplasms. The recently published International Consensus Classification of myeloid neoplasms revised the entities included in the MDS/MPN category as well as criteria for their diagnosis. In addition to the presence of one or more increased peripheral blood cell counts as evidence of myeloproliferative features, concomitant cytopenia as evidence of ineffective hematopoiesis is now an explicit requirement to diagnose the diseases included in this category...
January 2023: Virchows Archiv: An International Journal of Pathology
#27
JOURNAL ARTICLE
mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome.
Zhengping Huang, Xiaomeng You, Liang Chen, Yan Du, Kailey Brodeur, Hyuk Jee, Qiang Wang, Grace Linder, Roxane Darbousset, Pierre Cunin, Margaret H Chang, Alexandra Wactor, Brian M Wauford, Marc J C Todd, Kevin Wei, Ying Li, Anais Levescot, Yoichiro Iwakura, Virginia Pascual, Nicole E Baldwin, Pierre Quartier, Tianwang Li, Maria T Gianatasio, Robert P Hasserjian, Lauren A Henderson, David B Sykes, Elizabeth D Mellins, Scott W Canna, Julia F Charles, Peter A Nigrovic, Pui Y Lee
Still's disease is a severe inflammatory syndrome characterized by fever, skin rash and arthritis affecting children and adults. Patients with Still's disease may also develop macrophage activation syndrome, a potentially fatal complication of immune dysregulation resulting in cytokine storm. Here we show that mTORC1 (mechanistic target of rapamycin complex 1) underpins the pathology of Still's disease and macrophage activation syndrome. Single-cell RNA sequencing in a murine model of Still's disease shows preferential activation of mTORC1 in monocytes; both mTOR inhibition and monocyte depletion attenuate disease severity...
November 28, 2022: Nature Communications
#28
JOURNAL ARTICLE
Rory M Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
November 17, 2022: Cancer
#29
EDITORIAL
Attilio Orazi, Robert P Hasserjian, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi, Daniel A Arber
No abstract text is available yet for this article.
October 31, 2022: American Journal of Hematology
#30
REVIEW
Robert P Hasserjian, Attilio Orazi, Alberto Orfao, Maria Rozman, Sa A Wang
The International Consensus Classification (ICC) of myeloid neoplasms and acute leukemia has updated the classification of myelodysplastic syndromes (MDSs) and placed MDS in a broader group of clonal cytopenias that includes clonal cytopenia of undetermined significance (CCUS) and related entities. Although subject to some interobserver variability and lack of specificity, morphologic dysplasia remains the main feature that distinguishes MDS from other clonal cytopenias and defines MDS as a hematologic malignancy...
January 2023: Virchows Archiv: An International Journal of Pathology
#31
REVIEW
Olga K Weinberg, Anna Porwit, Attilio Orazi, Robert P Hasserjian, Kathryn Foucar, Eric J Duncavage, Daniel A Arber
Acute myeloid leukemias (AMLs) are overlapping hematological neoplasms associated with rapid onset, progressive, and frequently chemo-resistant disease. At diagnosis, classification and risk stratification are critical for treatment decisions. A group with expertise in the clinical, pathologic, and genetic aspects of these disorders developed the International Consensus Classification (ICC) of acute leukemias. One of the major changes includes elimination of AML with myelodysplasia-related changes group, while creating new categories of AML with myelodysplasia-related cytogenetic abnormalities, AML with myelodysplasia-related gene mutations, and AML with mutated TP53...
January 2023: Virchows Archiv: An International Journal of Pathology
#32
JOURNAL ARTICLE
Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel T Starczynowski, Guillermo F Sanz, David A Sallman, Valeria Santini, Gail J Roboz, Mrinal M Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D Nimer, Ravindra Majeti, Richard F Little, Steven D Gore, Alan F List, Vijay Kuchroo, Rami S Komrokji, Tae Kon Kim, Nina Kim, Christopher S Hourigan, Robert P Hasserjian, Stephanie Halene, Elizabeth A Griffiths, Peter L Greenberg, Maria E Figueroa, Pierre Fenaux, Fabio Efficace, Amy E DeZern, Matteo G Della Porta, Naval G Daver, Jane E Churpek, Hetty E Carraway, Andrew M Brunner, Uma Borate, John M Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P Steensma, Mikkael A Sekeres, Rena J Buckstein, Amer M Zeidan
No abstract text is available yet for this article.
October 19, 2022: Blood Advances
#33
JOURNAL ARTICLE
David B Chou, Brooke A Furlong, Ryan R Posey, Christos Kyprianou, Lucy R O'Sullivan, Rhiannon David, Suzanne J Randle, Urszula M Polanska, Jon Travers, Jelena Urosevic, John N Hutchinson, Jianwei Che, Anna M Howley, Robert P Hasserjian, Rachelle Prantil-Baun, Donald E Ingber
Drug-induced cytopenias are a prevalent and significant issue that worsens clinical outcomes and hinders the effective treatment of cancer. While reductions in blood cell numbers are classically associated with traditional cytotoxic chemotherapies, they also occur with newer targeted small molecules and the factors that determine the hematotoxicity profiles of oncologic drugs are not fully understood. Here, we explore why some Aurora kinase inhibitors cause preferential neutropenia. By studying drug responses of healthy human hematopoietic cells in vitro and analyzing existing gene expression datasets, we provide evidence that the enhanced vulnerability of neutrophil-lineage cells to Aurora kinase inhibition is caused by early developmental changes in ATP-binding cassette (ABC) transporter expression...
October 12, 2022: Nature Communications
#34
JOURNAL ARTICLE
Eric J Duncavage, Adam Bagg, Robert P Hasserjian, Courtney D DiNardo, Lucy A Godley, Ilaria Iacobucci, Siddhartha Jaiswal, Luca Malcovati, Alessandro M Vannucchi, Keyur P Patel, Daniel A Arber, Maria E Arcila, Rafael Bejar, Nancy Berliner, Michael J Borowitz, Susan Branford, Anna L Brown, Catherine A Cargo, Hartmut Döhner, Brunangelo Falini, Guillermo Garcia-Manero, Torsten Haferlach, Eva Hellström-Lindberg, Annette S Kim, Jeffery M Klco, Rami Komrokji, Mignon Lee-Cheun Loh, Sanam Loghavi, Charles G Mullighan, Seishi Ogawa, Attilio Orazi, Elli Papaemmanuil, Andreas Reiter, David M Ross, Michael Savona, Akiko Shimamura, Radek C Skoda, Francesc Solé, Richard M Stone, Ayalew Tefferi, Matthew J Walter, David Wu, Benjamin L Ebert, Mario Cazzola
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today...
November 24, 2022: Blood
#35
REVIEW
Alexandar Tzankov, Kaaren K Reichard, Robert P Hasserjian, Daniel A Arber, Attilio Orazi, Sa A Wang
This review addresses changes and updates in eosinophilic disorders under the International Consensus Classification (ICC). The previous category of myeloid/lymphoid neoplasm with eosinophilia (M/LN-eo) and a specific gene rearrangement is changed to M/LN-eo with tyrosine kinase gene fusions to reflect the underlying genetic lesions. Two new members, M/LN-eo with ETV6::ABL1 fusion and M/LN-eo with various FLT3 fusions, have been added to the category; and M/LN-eo with PCM1::JAK2 and its genetic variants ETV6::JAK2 and BCR::JAK2 are recognized as a formal entity from their former provisional status...
September 7, 2022: Virchows Archiv: An International Journal of Pathology
#36
JOURNAL ARTICLE
Baris Boyraz, Miriam D Post, Robert P Hasserjian, Esther Oliva
Follicular dendritic cell sarcoma is a rare dendritic/histiocytic tumor of intermediate malignant potential, which often involves extranodal sites, most commonly the gastrointestinal tract and mediastinum with only 5 cases reported in the female genital tract. We present the clinical and pathologic features of 2 such examples arising in the uterine corpus. Both patients (63 and 72-yr old) presented with postmenopausal bleeding and underwent an endometrial biopsy diagnostic of follicular dendritic cell sarcoma that was followed by hysterectomy...
August 5, 2022: International Journal of Gynecological Pathology
#37
JOURNAL ARTICLE
Megan J Fitzpatrick, Leonardo Boiocchi, Amir T Fathi, Andrew M Brunner, Robert P Hasserjian, Valentina Nardi
AIMS: TP53-mutated acute myeloid leukaemia (AML) is associated with an adverse prognosis and poor response to traditional chemotherapy regimens. Next-generation sequencing (NGS) is considered the gold standard method to determine TP53-mutational status; however, molecular assays are costly and time-consuming. In contrast, immunohistochemistry (IHC) can be performed within 1 day of biopsy. We sought to determine an optimal threshold of staining with p53 IHC to predict TP53-mutational status...
July 23, 2022: Histopathology
#38
JOURNAL ARTICLE
Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jessop, Alexander A Farahani, Mari Mino-Kenudson, Jill Allen, Lipika Goyal, Aparna Parikh, Joseph Misdraji, Ganesh Shankar, Justin T Jordan, Maria Martinez-Lage, Matthew Frosch, Timothy Graubert, Amir T Fathi, Gabriela S Hobbs, Robert P Hasserjian, Noopur Raje, Jeremy Abramson, Joel H Schwartz, Ryan J Sullivan, David Miller, Mai P Hoang, Steven Isakoff, Amy Ly, Sara Bouberhan, Jaclyn Watkins, Esther Oliva, Lori Wirth, Peter M Sadow, William Faquin, Gregory M Cote, Yin P Hung, Xin Gao, Chin-Lee Wu, Salil Garg, Miguel Rivera, Long P Le, A John Iafrate, Dejan Juric, Ephraim P Hochberg, Jeffrey Clark, Aditya Bardia, Jochen K Lennerz
BACKGROUND: Precision oncology relies on molecular diagnostics, and the value-proposition of modern healthcare networks promises a higher standard of care across partner sites. We present the results of a clinical pilot to standardize precision oncology workflows. METHODS: Workflows are defined as the development, roll-out, and updating of disease-specific molecular order sets. We tracked the timeline, composition, and effort of consensus meetings to define the combination of molecular tests...
November 3, 2022: Oncologist
#39
JOURNAL ARTICLE
Hartmut Döhner, Andrew H Wei, Frederick R Appelbaum, Charles Craddock, Courtney D DiNardo, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Lucy A Godley, Robert P Hasserjian, Richard A Larson, Ross L Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M Stein, Martin S Tallman, Hwei-Fang Tien, Jianxiang Wang, Agnieszka Wierzbowska, Bob Löwenberg
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors...
September 22, 2022: Blood
#40
EDITORIAL
Robert P Hasserjian
No abstract text is available yet for this article.
July 7, 2022: Blood
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
